Side-by-side comparison of AI visibility scores, market position, and capabilities
MIT-founded home blood testing company measuring 17 biomarkers via mail-in kits; Khosla-backed developing photonic chip for instant at-home results competing with Everlywell.
SiPhox Health is a home blood testing company founded by MIT scientists that provides mail-in blood test kits measuring 17 key biomarkers — inflammation markers (CRP, homocysteine), cardiovascular health (LDL, HDL, triglycerides, ApoB), metabolic health (HbA1c, glucose, insulin), and hormone levels (testosterone, DHEA, cortisol) — with results delivered within days and integrated with an app for trend tracking and health guidance. Founded in 2020 by Diedrik Vermeulen and Michael Dubrovsky, SiPhox Health is backed by Khosla Ventures, Intel Capital, and Y Combinator.\n\nSiPhox's current product uses at-home finger-prick blood collection with mail-in testing — customers order a $95 kit, collect a small blood sample at home, and mail it to SiPhox's CLIA-certified lab for analysis. The $16/month membership provides regular testing on a quarterly or customizable schedule, enabling biomarker trend monitoring over time rather than single point-in-time snapshots. The underlying technology vision is a photonic chip (silicon photonics-based biosensor) that would enable instant at-home blood analysis without lab processing, with FDA clearance targeted for 2026.\n\nIn 2025, SiPhox Health competes in the home diagnostics and consumer health testing market with Everlywell (the leading at-home test kit brand), Function Health (comprehensive blood panel membership), InsideTracker, and traditional lab companies (LabCorp, Quest Diagnostics) for consumer blood testing. The longevity and proactive health monitoring movement has driven demand for comprehensive biomarker testing beyond what annual physicals provide. The potential photonic chip breakthrough would represent a significant technological leap — enabling truly point-of-care diagnostics without lab infrastructure. The 2025 strategy focuses on growing the biomarker panel subscription business, advancing the photonic chip development toward FDA clearance, and building clinical evidence for the personalized health intervention recommendations.
$1.7B annual revenue; 160K+ providers, 117M patients; 18.15% EHR market share; 6,713+ companies using 2025; acquired by Bain Capital & Hellman & Friedman Nov 2021 at $17B; AI interoperability 2025
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on the principle that healthcare administration should be managed as a service — with athenahealth absorbing the complexity of payer rule updates, regulatory compliance, and billing workflows so that physicians and clinical staff can focus entirely on patient care. Its cloud-native architecture, deployed before most EHR competitors moved to the cloud, remains a core technical differentiator.\n\nathenahealth's platform — athenaOne — integrates EHR, revenue cycle management, patient engagement, and care coordination in a single system used by over 160,000 providers across 117 million patient records. The company serves ambulatory practices ranging from solo physicians to large health systems and medical groups. Its continuously updated rules engine processes millions of payer transactions daily, enabling higher clean claim rates and faster reimbursement compared to on-premise EHR alternatives. athenahealth holds an 18.15% share of the US ambulatory EHR market.\n\nathenahealth is currently owned by a private equity consortium of Bain Capital and Hellman & Friedman, which acquired the company in 2019 for $5.7 billion. Annual revenue stands at approximately $1.7 billion. The company competes with Epic, eClinicalWorks, and Oracle Health in the ambulatory EHR market. Its managed-service model, shared payer network data, and cloud-native infrastructure continue to make it a compelling choice for ambulatory providers who prioritize revenue cycle performance and reduced administrative burden.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.